Grudzinski, Amy Nicole; Hakim, Zafar; Cox, Emily R.; … - In: PharmacoEconomics 15 (1999) 3, pp. 229-240
The introduction of expensive disease-modifying agents for the treatment of multiple sclerosis (MS) has created the potential for patients with MS to become higher contributors to healthcare spending. In an attempt to make formulary and reimbursement choices for these agents, decision-makers may...